Among them, LGK974, a small-molecule inhibitor of PORCN which was developed as an anti-tumor drug candidate, has been shown to be effective in tumor models of murine breast cancer, human head and neck squamous cell carcinoma8 and glioblastoma9. This evidence concerns the gene PORCN and neoplasm.